BRPI0909910A2 - "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso" - Google Patents

"método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"

Info

Publication number
BRPI0909910A2
BRPI0909910A2 BRPI0909910A BRPI0909910A BRPI0909910A2 BR PI0909910 A2 BRPI0909910 A2 BR PI0909910A2 BR PI0909910 A BRPI0909910 A BR PI0909910A BR PI0909910 A BRPI0909910 A BR PI0909910A BR PI0909910 A2 BRPI0909910 A2 BR PI0909910A2
Authority
BR
Brazil
Prior art keywords
lupus erythematosus
systemic lupus
les
likelihood
inhibiting
Prior art date
Application number
BRPI0909910A
Other languages
English (en)
Inventor
Clos Terry W Du
Mold Carolyn
Original Assignee
Stc Unm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stc Unm filed Critical Stc Unm
Publication of BRPI0909910A2 publication Critical patent/BRPI0909910A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1745—C-reactive proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
BRPI0909910A 2008-06-03 2009-06-02 "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso" BRPI0909910A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13074908P 2008-06-03 2008-06-03
PCT/US2009/003338 WO2009148566A2 (en) 2008-06-03 2009-06-02 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis

Publications (1)

Publication Number Publication Date
BRPI0909910A2 true BRPI0909910A2 (pt) 2016-10-11

Family

ID=41398720

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909910A BRPI0909910A2 (pt) 2008-06-03 2009-06-02 "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"

Country Status (5)

Country Link
US (1) US20130072445A9 (pt)
EP (1) EP2303306A4 (pt)
JP (1) JP2011522044A (pt)
BR (1) BRPI0909910A2 (pt)
WO (1) WO2009148566A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503351RA (en) 2010-01-19 2015-06-29 Harvard College Engineered Opsonin for Pathogen Detection and Treatment
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3848045A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
EP3965885B1 (en) * 2019-05-09 2025-03-26 Truvian Sciences, Inc. Methods and compositions for reversing platelet clumping
IL298245A (en) 2020-05-18 2023-01-01 Truvian Sciences Inc An optical assembly for continuous scanning and a method for using it
US12636859B2 (en) 2020-09-22 2026-05-26 Truvian Sciences, Inc. Methods for bonding plastics and components made by the same
USD1116151S1 (en) 2023-05-03 2026-03-03 Truvian Sciences, Inc. Monolayer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
WO2005056044A1 (en) * 2003-10-23 2005-06-23 Terry Du Clos Use of c-reactive protein to treat immune complex-mediated renal disease
WO2007050661A2 (en) * 2005-10-26 2007-05-03 Science & Technology Corporation @ Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
CA2670125A1 (en) * 2006-11-06 2008-05-15 Stc.Unm Suppressive macrophages, c-reactive protein and the treatment of systemic lupus erythematosus and immune thrombocytopenic purpura

Also Published As

Publication number Publication date
EP2303306A4 (en) 2012-08-22
US20130072445A9 (en) 2013-03-21
WO2009148566A2 (en) 2009-12-10
EP2303306A2 (en) 2011-04-06
WO2009148566A3 (en) 2010-02-25
US20110152202A1 (en) 2011-06-23
JP2011522044A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
BRPI1011760A2 (pt) método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante.
WO2008131089A3 (en) Reduction of infection associated with medical device
EP2650002A4 (en) BIFIDOBACTERIUM CECT 7765 AND ITS USE IN THE PREVENTION AND / OR TREATMENT OF OVERWEIGHT, ADIPOSITAS AND SIMILAR ILLNESS
IL246181A0 (en) Methods of producing retinal pigment epithelium (rpe) cells, compositions comprising the same, and uses thereof in the preparation of medicaments for treating or preventing a condition characterized by retinal degeneration
IL219876A (en) Antibody or fragment thereof against human b7-h1, compositions comprising same and use thereof in the preparation of medicaments
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP2349401A4 (en) ONE-WAY INFUSION DEVICE WITH REDUNDANT VALVE SAFETY
IL215603A0 (en) Human protein scaffold with controlled serum pharmacokinetics, compositions comprising the same and uses thereof
CL2007001847A1 (es) Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
BRPI0718307A2 (pt) Uso de oligossacarídeos indigeríveis, composição nutricional, oligossacarídeos indigeríveis, e, método para melhora de resistência à insulina, prevenção da queda glicêmica pós-prandial e/ou diminuição da resposta à glicose pós-prandial de uma refeição
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
WO2010045407A3 (en) Reduction of infection associated with medical device
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
BRPI0817905A2 (pt) Utilização de uma cepa de bifidobacterium, para o preparo de uma composição destinada à prevenção e/ou ao tratamento de manifestações do tipo alérgicas
BRPI0813602A2 (pt) "dispositivo de travamento, nacela de turbojato e aeronave"
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
EP3378415A4 (en) IN VIVO RESIDENTIAL ELEMENT AND POSITIONING DEVICE FOR IN VIVO RESIDENTIAL ELEMENTS WITH THIS IN VIVO RESIDENTIAL ELEMENT
IL289943A (en) Medicinal and/or pharmaceutical compositions for insertion into a blister, preparation and uses
WO2009046015A3 (en) Combination therapies for treating type 1 diabetes
BRPI0922908A2 (pt) "composição compreendendo pelo menos dois cicloalquilmeticonas diferentes e uso deste".
EP3939608A4 (en) IMMUNITY ENHANCING ADJUVANT ADMINISTRATED IN COMBINATION WITH AN OIL EMULSION, AND FOOT AND MOUTH DISEASE VACCINE COMPOSITION COMPRISING THE SAME
CL2013000709A1 (es) Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).
BRPI0711136A2 (pt) uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: OBSERVA-SE QUE A PRIORIDADE REQUERIDA US 61/130,749 DE 03.06.2008 POSSUI DEPOSITANTE DIFERENTE DO INFORMADO NA ENTRADA NA FASE NACIONAL E SUA RESPECTIVA CESSAO NAO FOI APRESENTADA, MOTIVO PELO QUAL SERA DADA PERDA DESTA PRIORIDADE, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]